Sentences with phrase «team translational cancer research»

This work was supported by a Stand Up To Cancer — Prostate Cancer Foundation — Prostate Dream Team Translational Cancer Research Grant (grant number: SU2C - AACR - DT0812).

The research reported by the Johns Hopkins, MD Anderson, and Baylor group was funded by grants from the National Institutes of Health, the National Institute of Dental and Craniofacial Research, the Cancer Prevention Research Institute of Texas, the AACR Stand Up To Cancer - Dream Team Translational Cancer Research Grant, and the Virginia and D.K. Ludwig Fund for Cancer Research.

(The Stand Up to Cancer Prostate Cancer Foundation Prostate Dream Team Translational Cancer Research Grant is made possible by the generous support of the Movember Foundation.

Not exact matches

A team under Professor Scheffler, consisting of researchers from the Bonn University Hospital, the Life & Brain Center, The German Consortium for Translational Cancer Research, Tufts University Boston / Massachusetts, and other institutes in the USA, has now developed a new method that is expected to combat such complex brain tumors better.

Joining forces with dermatologists and oncologists from the University Hospital in Zurich and backed by the University Research Priority Program «Translational Cancer Research,» Sommer's team was able to demonstrate that, in melanoma cells, the epigenetic factor EZH2 controls genes that govern tumor growth as well as genes that are important for the formation of metastases.

The research team is led by Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine and director of Translational Research in the Abramson Cancer Center, along with David Porter, MD, the Jodi Fisher Horowitz Professor in Leukemia Care Excellence and director of Blood and Marrow Transplantation in the Abramson Cancerresearch team is led by Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine and director of Translational Research in the Abramson Cancer Center, along with David Porter, MD, the Jodi Fisher Horowitz Professor in Leukemia Care Excellence and director of Blood and Marrow Transplantation in the Abramson CancerResearch in the Abramson Cancer Center, along with David Porter, MD, the Jodi Fisher Horowitz Professor in Leukemia Care Excellence and director of Blood and Marrow Transplantation in the Abramson Cancer Center.

At the dinner, Parker also received the organization's highest honor for lay individuals, the Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research, for his outspoken endorsement of cancer immunotherapy and substantial financial support of the Cancer Immunology Translational Research Dream Team that is jointly funded by CRI and Stand Up To Cancer, an organization to which Parker has strongCancer Research, for his outspoken endorsement of cancer immunotherapy and substantial financial support of the Cancer Immunology Translational Research Dream Team that is jointly funded by CRI and Stand Up To Cancer, an organization to which Parker has strongcancer immunotherapy and substantial financial support of the Cancer Immunology Translational Research Dream Team that is jointly funded by CRI and Stand Up To Cancer, an organization to which Parker has strongCancer Immunology Translational Research Dream Team that is jointly funded by CRI and Stand Up To Cancer, an organization to which Parker has strongCancer, an organization to which Parker has strong ties.

With a team of over 200 researchers, Sanford Research is comprised of eight groups that bridge bench, translational and clinical research including: Cancer Biology and Immunotherapies, Pediatrics and Rare Diseases, Diabetes, Cellular Therapies and Stem Cell Biology, Enabling Technology, Environmental Influences on Health and Disease, Genetics and Genomics, and PopulationResearch is comprised of eight groups that bridge bench, translational and clinical research including: Cancer Biology and Immunotherapies, Pediatrics and Rare Diseases, Diabetes, Cellular Therapies and Stem Cell Biology, Enabling Technology, Environmental Influences on Health and Disease, Genetics and Genomics, and Populationresearch including: Cancer Biology and Immunotherapies, Pediatrics and Rare Diseases, Diabetes, Cellular Therapies and Stem Cell Biology, Enabling Technology, Environmental Influences on Health and Disease, Genetics and Genomics, and Population Health.

Together, this translational program is developed within the National Cancer and Cognition Platform (CNO / Ligue Nationale contre le cancer), with the aim to collaborate in a structured way with French oncology groups, research teams as well as pharmaceutical industry, by providing preclinical models and guidance on standard operating procedures for ancillary or future studies in identified population atCancer and Cognition Platform (CNO / Ligue Nationale contre le cancer), with the aim to collaborate in a structured way with French oncology groups, research teams as well as pharmaceutical industry, by providing preclinical models and guidance on standard operating procedures for ancillary or future studies in identified population atcancer), with the aim to collaborate in a structured way with French oncology groups, research teams as well as pharmaceutical industry, by providing preclinical models and guidance on standard operating procedures for ancillary or future studies in identified population at risk.

The study, «Melanoma - intrinsic β - catenin signalling prevents anti-tumour immunity,» was funded by a Team Science Award from the Melanoma Research Alliance and a Translational Research Grant from the Cancer Research Institute.

The study, by O'Donnell; head and neck cancer specialists Everett E. Vokes, MD, physician - in - chief and chair of the Department of Medicine, and Ezra Cohen, MD; and several investigators from the CPT team and Department of Human Genetics, was published in the May 2011 Translational Research.

The Department of Translational Research hosts 5 technological platforms (Genomics, Protein arrays, High - content screening, Experimental radiotherapy and Preclinical investigation), 4 labeled teams (resistance to therapy in breast cancers, translational pediatrics, angiogenesis, and immunotherapy) and 3 emergent teams (Circulating biomarkers, uveal melanoma, and new targets in triple negative breTranslational Research hosts 5 technological platforms (Genomics, Protein arrays, High - content screening, Experimental radiotherapy and Preclinical investigation), 4 labeled teams (resistance to therapy in breast cancers, translational pediatrics, angiogenesis, and immunotherapy) and 3 emergent teams (Circulating biomarkers, uveal melanoma, and new targets in triple negative bretranslational pediatrics, angiogenesis, and immunotherapy) and 3 emergent teams (Circulating biomarkers, uveal melanoma, and new targets in triple negative breast cancers).

In 2016, Dmitry I. Gabrilovich, M.D., Ph.D., program leader of Wistar's Translational Tumor Immunology program, and his research team identified a marker for myeloid - derived suppressor cells (MDSCs), a population of immune cells implicated in tumor resistance to various types of cancer treatment, including targeted therapies, chemotherapy and immunotherapy.